They developed a mutated form of IFN-α2 coupled to a single domain antibody specific for the DC receptor Clec9A, which is up to 1000-fold more potent on DC target cells and yields strong antitumor immune responses resulting in complete tumor regression and long-lasting protection in melanoma, breast cancer, and lymphoma mouse models without significant toxicity [130]. This evidence concerns the gene CLEC9A and lymphoma.